MAPK8IP2 is a potential prognostic biomarker and promote tumor progression in prostate cancer

Abstract Background MAPK8IP2 is one of the JNK-interacting proteins (JIPs) family members, and is involved in the regulation of the JNK and P38 MAPK signaling pathways. MAPK8IP2 has been reported to be closely associated with several cancers. However, the biological function of MAPK8IP2 in prostate...

Full description

Bibliographic Details
Main Authors: Zhenhao Zeng, Wenrui He, Yi Jiang, Hao Jiang, Xiaofeng Cheng, Wen Deng, Xiaochen Zhou, Cheng Zhang, Gongxian Wang
Format: Article
Language:English
Published: BMC 2022-11-01
Series:BMC Cancer
Subjects:
Online Access:https://doi.org/10.1186/s12885-022-10259-2
_version_ 1798019113592815616
author Zhenhao Zeng
Wenrui He
Yi Jiang
Hao Jiang
Xiaofeng Cheng
Wen Deng
Xiaochen Zhou
Cheng Zhang
Gongxian Wang
author_facet Zhenhao Zeng
Wenrui He
Yi Jiang
Hao Jiang
Xiaofeng Cheng
Wen Deng
Xiaochen Zhou
Cheng Zhang
Gongxian Wang
author_sort Zhenhao Zeng
collection DOAJ
description Abstract Background MAPK8IP2 is one of the JNK-interacting proteins (JIPs) family members, and is involved in the regulation of the JNK and P38 MAPK signaling pathways. MAPK8IP2 has been reported to be closely associated with several cancers. However, the biological function of MAPK8IP2 in prostate cancer (PCa) remains unclear. Methods MAPK8IP2 expression in PCa and subgroups of PCa was analyzed by public databases. The prognostic role of MAPK8IP2 in prostate cancer was analyzed using the Cox regression method. The potential mechanism by which MAPK8IP2 affects PCa progression was investigated by utilizing public data, including genetic alteration, DNA methylation, m6A methylation, and immune infiltration data. We further performed in vitro assays to validate the effect of MAPK8IP2 on PCa cell proliferation, migration and invasion. Results MAPK8IP2 is highly expressed in PCa tissues. Overexpression of MAPK8IP2 is associated with adverse clinicopathological factors and a poor prognosis in PCa. Receiver operating curve analysis showed that MAPK8IP2 can distinguish PCa tissues from non-PCa tissues with a certain accuracy (AUC = 0.814). The MAPK8IP2 genetic alteration rate was 2.6% and MAPK8IP2 alterations correlated with a poor prognosis. We also found that CDK12 and TP53 mutations were associated with MAPK8IP2 expression. The DNA methylation level of MAPK8IP2 was higher in primary tumors than in normal tissues, and the high MAPK8IP2 DNA methylation group of PCa patients had poor survival. Enrichment analysis indicated that MAPK8IP2 was involved in the MAPK signaling pathway. In vitro, knockdown of MAPK8IP2 inhibited PCa cell proliferation, migration and invasion. Conclusion MAPK8IP2 is a potential target for PCa treatment and can serve as a novel biomarker for PCa diagnosis and prognosis evaluation.
first_indexed 2024-04-11T16:35:23Z
format Article
id doaj.art-f727b8a270884c7fabb5c0bd77904a55
institution Directory Open Access Journal
issn 1471-2407
language English
last_indexed 2024-04-11T16:35:23Z
publishDate 2022-11-01
publisher BMC
record_format Article
series BMC Cancer
spelling doaj.art-f727b8a270884c7fabb5c0bd77904a552022-12-22T04:13:51ZengBMCBMC Cancer1471-24072022-11-0122111810.1186/s12885-022-10259-2MAPK8IP2 is a potential prognostic biomarker and promote tumor progression in prostate cancerZhenhao Zeng0Wenrui He1Yi Jiang2Hao Jiang3Xiaofeng Cheng4Wen Deng5Xiaochen Zhou6Cheng Zhang7Gongxian Wang8Department of Urology, The First Affiliated Hospital of Nanchang UniversityDepartment of Urology, The First Affiliated Hospital of Nanchang UniversityDepartment of Urology, The Second Affiliated Hospital of Nanchang UniversityDepartment of Ultrasound Medicine, The Second Affiliated Hospital of Nanchang UniversityDepartment of Urology, The First Affiliated Hospital of Nanchang UniversityDepartment of Urology, The First Affiliated Hospital of Nanchang UniversityDepartment of Urology, The First Affiliated Hospital of Nanchang UniversityDepartment of Urology, The First Affiliated Hospital of Nanchang UniversityDepartment of Urology, The First Affiliated Hospital of Nanchang UniversityAbstract Background MAPK8IP2 is one of the JNK-interacting proteins (JIPs) family members, and is involved in the regulation of the JNK and P38 MAPK signaling pathways. MAPK8IP2 has been reported to be closely associated with several cancers. However, the biological function of MAPK8IP2 in prostate cancer (PCa) remains unclear. Methods MAPK8IP2 expression in PCa and subgroups of PCa was analyzed by public databases. The prognostic role of MAPK8IP2 in prostate cancer was analyzed using the Cox regression method. The potential mechanism by which MAPK8IP2 affects PCa progression was investigated by utilizing public data, including genetic alteration, DNA methylation, m6A methylation, and immune infiltration data. We further performed in vitro assays to validate the effect of MAPK8IP2 on PCa cell proliferation, migration and invasion. Results MAPK8IP2 is highly expressed in PCa tissues. Overexpression of MAPK8IP2 is associated with adverse clinicopathological factors and a poor prognosis in PCa. Receiver operating curve analysis showed that MAPK8IP2 can distinguish PCa tissues from non-PCa tissues with a certain accuracy (AUC = 0.814). The MAPK8IP2 genetic alteration rate was 2.6% and MAPK8IP2 alterations correlated with a poor prognosis. We also found that CDK12 and TP53 mutations were associated with MAPK8IP2 expression. The DNA methylation level of MAPK8IP2 was higher in primary tumors than in normal tissues, and the high MAPK8IP2 DNA methylation group of PCa patients had poor survival. Enrichment analysis indicated that MAPK8IP2 was involved in the MAPK signaling pathway. In vitro, knockdown of MAPK8IP2 inhibited PCa cell proliferation, migration and invasion. Conclusion MAPK8IP2 is a potential target for PCa treatment and can serve as a novel biomarker for PCa diagnosis and prognosis evaluation.https://doi.org/10.1186/s12885-022-10259-2MAPK8IP2Prostate cancerMethylationPrognosisTumor progression
spellingShingle Zhenhao Zeng
Wenrui He
Yi Jiang
Hao Jiang
Xiaofeng Cheng
Wen Deng
Xiaochen Zhou
Cheng Zhang
Gongxian Wang
MAPK8IP2 is a potential prognostic biomarker and promote tumor progression in prostate cancer
BMC Cancer
MAPK8IP2
Prostate cancer
Methylation
Prognosis
Tumor progression
title MAPK8IP2 is a potential prognostic biomarker and promote tumor progression in prostate cancer
title_full MAPK8IP2 is a potential prognostic biomarker and promote tumor progression in prostate cancer
title_fullStr MAPK8IP2 is a potential prognostic biomarker and promote tumor progression in prostate cancer
title_full_unstemmed MAPK8IP2 is a potential prognostic biomarker and promote tumor progression in prostate cancer
title_short MAPK8IP2 is a potential prognostic biomarker and promote tumor progression in prostate cancer
title_sort mapk8ip2 is a potential prognostic biomarker and promote tumor progression in prostate cancer
topic MAPK8IP2
Prostate cancer
Methylation
Prognosis
Tumor progression
url https://doi.org/10.1186/s12885-022-10259-2
work_keys_str_mv AT zhenhaozeng mapk8ip2isapotentialprognosticbiomarkerandpromotetumorprogressioninprostatecancer
AT wenruihe mapk8ip2isapotentialprognosticbiomarkerandpromotetumorprogressioninprostatecancer
AT yijiang mapk8ip2isapotentialprognosticbiomarkerandpromotetumorprogressioninprostatecancer
AT haojiang mapk8ip2isapotentialprognosticbiomarkerandpromotetumorprogressioninprostatecancer
AT xiaofengcheng mapk8ip2isapotentialprognosticbiomarkerandpromotetumorprogressioninprostatecancer
AT wendeng mapk8ip2isapotentialprognosticbiomarkerandpromotetumorprogressioninprostatecancer
AT xiaochenzhou mapk8ip2isapotentialprognosticbiomarkerandpromotetumorprogressioninprostatecancer
AT chengzhang mapk8ip2isapotentialprognosticbiomarkerandpromotetumorprogressioninprostatecancer
AT gongxianwang mapk8ip2isapotentialprognosticbiomarkerandpromotetumorprogressioninprostatecancer